Orexigen (OREX)

OREX partnered with Takeda on getting FDA approval of Contrave. March, 2016, Takeda said thanks, nice knowin' ya, and gave Contrave back to OREX.

Contrave was also approved in the EU named Mysimba.

From another PR about the BK filing, there are these business hightlights:

Recent Business Highlights
Contrave is the No.1 prescribed weight loss brand in the U.S.
>2.3M prescriptions have been written in the U.S. since launch
>100,000 unique U.S. prescribers of Contrave since launch
23% year-over-year TRx growth in the U.S. in 2017
21% year-over-year TRx growth in the U.S. in 2018 to date
All-time highs in weekly TRx volume (19,247), branded TRx market share (48.7%) and telemedicine/home delivery volume (2,288) achieved in early March 2018
2017 U.S. Contrave net sales of ~$75M compared to ~$47M2 in 2016
2017 global supply revenue from international partners of ~$13M compared to ~$5M in 2016
Implemented streamlined and innovative U.S. commercial model, with expected annual savings of ~$40M in 2018, under the current plan, compared to 2017
Launched in 24 of 68 partnered countries, with an additional 14 launches currently planned in 2018
U.S. market exclusivity solidified through 2030 following favorable ruling in patent litigation
Recent FDA acceptance of a significantly more efficient approach for completion of a cardiovascular outcomes post marketing requirement

 
Source: IQVIA NPA data Sept 2014 through Jan 2018 and the IQVIA Persistence and Adherence study conducted June 2016
Includes net sales as reported by our former partner pursuant to the terms of our former collaboration agreement for periods prior to the completed acquisition of Contrave, coupled with net sales as recorded by Orexigen after the completed acquisition of Contrave.

About Contrave and Mysimba
Contrave, marketed as Mysimba in the European Union, is a prescription-only, FDA-approved weight-loss medication believed to work on two areas of the brain—the hunger center and the reward system—to reduce hunger and help control cravings. The exact neurochemical effects of Contrave/Mysimba leading to weight loss are not fully understood. Contrave/Mysimba contains two medicines, bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine and naltrexone, an opioid antagonist.
Contrave, approved by the FDA in September 2014, is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia).  In the European Union, Mysimba was approved in March 2015.